Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

In a leap forward for chronic kidney disease (CKD) screening, Healthy.io, the global leader in transforming the smartphone ...

Additionally, in January 2022, Lubrizol Life Science (LLS) Health, a global frontrunner in pharmaceutical research innovation ...

Credit: Max4e Photo/Shutterstock. Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment for geographic atrophy (GA). BI 771716 ...

The Middle Kingdom has seen a number of car-branded devices launched in the past few years, including from Nio and even Polestar. Now, there’s a new company appearing to join the fray ...